Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Multiple Myeloma 4 Smoldering Multiple Myeloma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Leukemia, Promyelocytic, Acute 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 7 blinatumomab 6 Cytarabine 6 fludarabine 5 Mercaptopurine 5 Methotrexate 4 fludarabine phosphate 3 Vincristine 3 Rituximab 3 Granulocyte Colony-Stimulating Factor 3 Etoposide 3 Drug Therapy 3 Dexamethasone 3 Daunorubicin 3 Asparaginase 3 Whole-Body Irradiation 2 Vindesine 2 Thioguanine 2 Teniposide 2 Stem Cell Transplantation 2 Prednisolone 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Interleukin-2 2 Doxorubicin 2 Cladribine 2 Blood Specimen Collection 2 Azacitidine 2 tisagenlecleucel 1 thymoglobulin 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neoplasm, Residual × Maintenance × Clear all

NCT02067143 2021-09-08

LAL1913

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed

Neoplasm Metastasis, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡